Here are the DEF 14A proxy statements from Cerus Corp (CERS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERS filings page.
Cerus Corporation is asking stockholders to vote at its June 2, 2026 virtual annual meeting on four key items: electing two directors, expanding its 2024 Equity Incentive Plan by 10 million shares, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as auditor for 2026.
The proxy also highlights Cerus’ INTERCEPT Blood System franchise and 2025 results, including $206.1 million in product revenue, a narrowed GAAP net loss of $15.6 million, positive non-GAAP adjusted EBITDA of $9.5 million, and positive operating cash flow for a second year.